View by Tumor Type
Colorectal Cancer
Home › All Therapies › Vectibix

Vectibix

panitumumab
EGFR Monoclonal Antibody FDA Approved 2006 Amgen
Route
IV
Half-Life
7.5 days
FDA Approved
2006
Manufacturer
Amgen
Navigation -->
1. Indications and Usage

CRC: Wild-type RAS mCRC: first-line with FOLFOX, or monotherapy.

2. Dosage and Administration

6 mg/kg IV Q2W over 60 min (>1000 mg over 90 min).

3. Dosage Forms and Strengths

Injection: 100 mg/5 mL; 400 mg/20 mL vials

4. Contraindications

None listed.

5. Warnings and Precautions
  • Dermatologic Toxicity: 90% incidence.
  • Infusion Reactions: Anaphylaxis reported.
  • Pulmonary Fibrosis: Fatal cases.
  • Embryo-Fetal Toxicity: Can cause fetal harm.
6. Adverse Reactions
Most Common Adverse Reactions

Skin Rash (90%), Acneiform Dermatitis (57%), Hypomagnesemia (38%), Fatigue (26%), Paronychia (25%), Nausea (23%), Diarrhea (21%), Conjunctivitis (15%)

Skin Rash
90%
Acneiform Dermatitis
57%
Hypomagnesemia
38%
Fatigue
26%
Paronychia
25%
Nausea
23%
Diarrhea
21%
Conjunctivitis
15%

Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.

7. Drug Interactions

Not expected to interact via CYP enzymes.

8. Use in Specific Populations
Pregnancy

Consult the full prescribing information for pregnancy-related considerations.

Lactation

Refer to prescribing information for lactation guidance.

Pediatric Use

Pediatric safety and efficacy information is detailed in the full label.

Hepatic/Renal Impairment

Dose modifications for organ impairment are specified in the complete prescribing information.

12. Clinical Pharmacology
Mechanism of Action

Fully human anti-EGFR IgG2 mAb blocking ligand binding and downstream RAS/RAF/MAPK signaling. Only effective in wild-type RAS tumors.

Pharmacokinetics

t½: ~7.5 days.

14. Clinical Studies

Clinical efficacy and safety data supporting the approval are available in the full prescribing information and from the clinical trials listed below.

Pivotal Clinical Trials
Additional Resources
📋 All Vectibix Trials on ClinicalTrials.gov ↗ 📚 PubMed: Vectibix Clinical Trials ↗
FDA-Approved Tumor Types

Vectibix has FDA-approved indications across the following cancer types covered on CancerDrugEvidence:

Colorectal Cancer
External Resources
📋 DailyMed Label ↗ 🏛️ FDA Drugs@FDA ↗ 🔬 ClinicalTrials.gov ↗ 📚 PubMed Pivotal Trials ↗
Important Notice: This page is intended as a navigational reference to the FDA-approved prescribing information for Vectibix. It does not replace the full prescribing information. Healthcare professionals should consult the complete package insert available at DailyMed before making prescribing decisions. Patient-specific factors should always guide clinical decision-making.

Frequently Asked Questions

What is Vectibix (panitumumab) approved for?

Vectibix (panitumumab) is an FDA-approved oncology agent. Refer to the full prescribing information for complete indication details.

How is Vectibix (panitumumab) administered?

Refer to the full prescribing information for dosing schedules, administration instructions, and dose modifications.

How does Vectibix (panitumumab) work?

Fully human anti-EGFR IgG2 mAb blocking ligand binding and downstream RAS/RAF/MAPK signaling. Only effective in wild-type RAS tumors.

What are the most common side effects?

Skin Rash (90%), Acneiform Dermatitis (57%), Hypomagnesemia (38%), Fatigue (26%), Paronychia (25%), Nausea (23%), Diarrhea (21%), Conjunctivitis (15%) Skin Rash 90% Acneiform Dermatitis 57% Hypomagnesemia 38% Fatigue 26% Paronychia 25% Nausea 23% Diarrhea 21% Conjunctivitis 15%

← All Therapies Full Prescribing Information ↗